ONCOLOGY PHARMA INC.

Inactive Instrument

Press Releases Oncology Pharma Inc. Other OTC

Equities

ONPH

US68235J2015

Press Releases

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Oncology Pharma : Conducting Interviews and Presentations with Investors to Pursue Next Steps to Forward The Development Process of Nanoemulsion Drug Delivery System	12/22/12	PU
Oncology Pharma : Conducting All The Preparations to Take Steps to Forward The Development Process of Nanoemulsion Drug Delivery System	29/22/29	PU
Oncology Pharma : Financial Statements (Unaudited) for the year ended March 31, 2022	06/22/06	PU
Oncology Pharma : Financial Statements for the period ended December 31, 2021	15/22/15	PU
Oncology Pharma : Disclosure Statement for the period ended December 31, 2021	15/22/15	PU
Oncology Pharma Inc :.	20/21/20	AQ
Oncology Pharma : Has Provided Initial Funding to NanoSmart Pharmaceuticals to Conduct Feasibility Studies for Initial Phases of IND-Enabling Activities	31/21/31	AQ
Oncology Pharma : Reveals Strategic Plans for Company Growth and Focus	16/21/16	AQ
Oncology Pharma : Vetting CROs to Develop Research Plan and Indications for Recently Licensed Cancer Combination Therapy	10/21/10	AQ
Oncology Pharma : Moves to Fund Lead Drug Formulation & IND-Enabling Studies	04/21/04	AQ
Oncology Pharma Signs Worldwide Licensing Agreement with Sybleu, Inc. for Commercialization of Chemotherapeutic Agent in Combination with a Bioactive Immunostimulatory Agent	26/21/26	GL
Oncology Pharma : Extends Licensing Agreement with NanoSmart Pharmaceuticals, Inc. for Veterinary Oncology	22/21/22	AQ
Oncology Pharma : is Pleased to Welcome New Chairman to Its Scientific Advisory Board	16/21/16	AQ
Oncology Pharma : Renews Licensing Agreement With Ribera Solutions LLC for Its Connect2Med Clinical Trials Platform	09/21/09	AQ
Oncology Pharma : Extends Its Licensing Agreement with NanoSmart Pharmaceuticals, Inc. for Human Oncology	03/21/03	AQ
Oncology Pharma Announces the Appointment Of New Chief Financial Officer	29/21/29	GL
Oncology Pharma Announces Extension of Letter of Intent with Kalos Therapeutics, Retained an Interim CEO and Approval of Reverse Stock Split	27/20/27	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

+201.5% on SUPER MICRO COMPUTER since our purchase on February 17, 2023

Replicate our performance

fermer